The North American Menopause Society (NAMS) recently announced the publication of its 2020 Genitourinary Syndrome of Menopause (GSM) position statement that included updated recommendations on the most current safe and effective therapeutic options for women with GSM. Despite having a variety of over-the-counter and prescription treatment options, GSM remains underdiagnosed and undertreated. Since the NAMS…
Use of antidepressants, beta-blockers, insulin linked to increase in BMI, waist circumference.
Gabapentin may be a beneficial therapeutic option for managing vasomotor symptoms in postmenopausal women.
Increase in dietary magnesium associated with reduced risk for fatal CHD in postmenopausal women
Benefit seen especially in older women and women initiating treatment within five years of menopause
Some excess risk persists for >10 years after ceasing therapy; magnitude varies with duration of use
High intake of vitamin B6 and B12 may increase the risk of hip fracture in postmenopausal women, according to the results of a recently published prospective cohort study.
This slideshow reviews drug information for Bijuva. Click here for the complete Bijuva monograph.
TherapeuticsMD announced the launch of Bijuva (estradiol and progesterone) capsules for use in women with a uterus for the treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause.
Results from 3 studies evaluating the interaction between Addyi (flibanserin; Sprout), a treatment for hypoactive sexual desire disorder in premenopausal women, and alcohol have been submitted to the FDA for review for inclusion in the product labeling.
